ZURA 241220 7.50P (ZURA241220P7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

ZURA241220P7500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 21 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Zura Bio Ltd - Trial Is Expected to Initiate in Q4 2024
ReutersNov 14 16:30 ET
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults With Systemic Sclerosis
BusinesswireNov 14 16:30 ET
H.C. Wainwright Maintains Zura Bio(ZURA.US) With Hold Rating, Maintains Target Price $5
Moomoo NewsNov 11 07:34 ET · Ratings
Cautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial Uncertainty
TipRanksNov 11 06:36 ET · Ratings
Chardan Capital Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $12
Moomoo NewsNov 9 09:31 ET · Ratings
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $15
Moomoo NewsNov 9 08:31 ET · Ratings

Comments

Jaguar8

Nov 14 15:32

NEWS

$Zura Bio (ZURA.US)$
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Methodman10

Oct 17 14:32

$Zura Bio (ZURA.US)$ big move ahead. daily chart looks great

Trytosaveabit

Jun 14 05:04

Update

$Zura Bio (ZURA.US)$ Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024

Drosen21

Jun 12 08:09

Hedgies may be confused over at Cantor…

$Zura Bio (ZURA.US)$ One is overweight and another to buy 🤫

Jaguar8

Jun 3 06:31

NEWS

$Zura Bio (ZURA.US)$
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...